FR2442839B1 - - Google Patents

Info

Publication number
FR2442839B1
FR2442839B1 FR7901413A FR7901413A FR2442839B1 FR 2442839 B1 FR2442839 B1 FR 2442839B1 FR 7901413 A FR7901413 A FR 7901413A FR 7901413 A FR7901413 A FR 7901413A FR 2442839 B1 FR2442839 B1 FR 2442839B1
Authority
FR
France
Prior art keywords
morpholine
phenoxy
methoxy
benzyl
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7901413A
Other languages
English (en)
French (fr)
Other versions
FR2442839A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmitalia Carlo Erba SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT1944978A external-priority patent/IT1093255B/it
Priority claimed from IT1945078A external-priority patent/IT1111676B/it
Priority claimed from IT30535/78A external-priority patent/IT1101724B/it
Priority claimed from IT3053378A external-priority patent/IT1160301B/it
Priority claimed from IT3053478A external-priority patent/IT1160302B/it
Application filed by Farmitalia Carlo Erba SRL filed Critical Farmitalia Carlo Erba SRL
Publication of FR2442839A1 publication Critical patent/FR2442839A1/fr
Application granted granted Critical
Publication of FR2442839B1 publication Critical patent/FR2442839B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/32—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to acyclic carbon atoms and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/16—Preparation of ethers by reaction of esters of mineral or organic acids with hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/41—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C07D265/33—Two oxygen atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR7901413A 1978-01-20 1979-01-19 Derives substitues de morpholine utiles comme medicaments et procede de leur preparation Granted FR2442839A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IT1944978A IT1093255B (it) 1978-01-20 1978-01-20 Derivati fenossialcanolaminici
IT1945078A IT1111676B (it) 1978-01-20 1978-01-20 Derivati della 2-fenossimetil-morfolina
IT30535/78A IT1101724B (it) 1978-12-05 1978-12-05 Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione
IT3053378A IT1160301B (it) 1978-12-05 1978-12-05 Derivati fenossialcanolaminici
IT3053478A IT1160302B (it) 1978-12-05 1978-12-05 Derivati della 2-fenossimentil-morfolina

Publications (2)

Publication Number Publication Date
FR2442839A1 FR2442839A1 (fr) 1980-06-27
FR2442839B1 true FR2442839B1 (Direct) 1984-07-27

Family

ID=27517788

Family Applications (2)

Application Number Title Priority Date Filing Date
FR7901413A Granted FR2442839A1 (fr) 1978-01-20 1979-01-19 Derives substitues de morpholine utiles comme medicaments et procede de leur preparation
FR7922678A Expired FR2430412B1 (fr) 1978-01-20 1979-09-11 Derives substitues de propanolamine utiles comme medicaments et procede de leur preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR7922678A Expired FR2430412B1 (fr) 1978-01-20 1979-09-11 Derives substitues de propanolamine utiles comme medicaments et procede de leur preparation

Country Status (24)

Country Link
US (2) US4229449A (Direct)
JP (1) JPS54148739A (Direct)
AT (1) AT371813B (Direct)
AU (1) AU525954B2 (Direct)
BG (1) BG61056B2 (Direct)
CA (1) CA1128942A (Direct)
CH (1) CH650245A5 (Direct)
CS (1) CS413391A3 (Direct)
CY (1) CY1172A (Direct)
DE (2) DE2901032C2 (Direct)
DK (1) DK156565C (Direct)
FI (1) FI71135C (Direct)
FR (2) FR2442839A1 (Direct)
GB (1) GB2014981B (Direct)
HK (1) HK5783A (Direct)
IE (1) IE47727B1 (Direct)
IL (1) IL56369A (Direct)
KE (1) KE3243A (Direct)
MY (1) MY8400018A (Direct)
NO (1) NO146953C (Direct)
NZ (1) NZ189418A (Direct)
SE (1) SE446727B (Direct)
SI (1) SI7910096A8 (Direct)
YU (1) YU42094B (Direct)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226523A (en) * 1978-11-17 1980-10-07 Energy Conversion Devices, Inc. Imaging device
GB8419683D0 (en) * 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2162517B (en) * 1984-08-01 1988-04-27 Erba Farmitalia Process for the preparation of 3-substituted derivatives of 1-amino-2-hydroxy-propane
DE3546929B4 (de) * 1984-08-02 2006-02-09 Pharmacia Italia S.P.A. 1,2-substituierte Derivate von 3-Phenoxy-3-Phenylpropan
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
GB8823405D0 (en) * 1988-10-05 1988-11-09 Erba Carlo Spa Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
WO1999015177A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
ATE301462T1 (de) 1998-04-09 2005-08-15 Pharmacia & Upjohn Co Llc Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden
IT1305322B1 (it) 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
ATE430144T1 (de) * 1998-12-29 2009-05-15 Pharmacia & Upjohn Co Llc Verfahren zur herstellung von arylethern
EP1459748B8 (en) * 1999-07-01 2005-06-08 Pharmacia & Upjohn Company LLC (S,S)-reboxetine for treating peripheral neuropathy
ATE364386T1 (de) * 1999-07-01 2007-07-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
AU2005220235B2 (en) * 1999-07-01 2007-05-10 Pharmacia & Upjohn Company Selective norepinephrine reuptake inhibitors and methods of using the same
US6387403B1 (en) 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
US20040048860A1 (en) * 2000-10-31 2004-03-11 Jes Olesen Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
US20050014843A1 (en) * 2001-11-30 2005-01-20 Allen Albert John Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
WO2003088958A2 (en) * 2002-04-18 2003-10-30 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson’s disease
NZ537521A (en) * 2002-08-14 2007-05-31 Pharmacia & Upjohn Co Llc Use of reboxetine for the treatment of hot flashes
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7417064B2 (en) * 2002-11-05 2008-08-26 Eli Lilly And Company 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake
TWI316511B (en) 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
BRPI0409492A (pt) * 2003-04-18 2006-05-02 Pharmacia & Up John Company Ll terapias de combinação
EP1708717B1 (en) * 2003-07-28 2011-10-05 Leslie Joe Dunaway Atomoxetine for treatment of allergic rhinitis and asthma
NZ545494A (en) 2003-09-12 2009-10-30 Pfizer Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
EP1675582A1 (en) * 2003-09-12 2006-07-05 Warner-Lambert Company LLC Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7491723B2 (en) * 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7531543B2 (en) * 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7365076B2 (en) * 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7419980B2 (en) * 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7402698B2 (en) * 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7524846B2 (en) * 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
JP5646126B2 (ja) 2003-12-11 2014-12-24 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法
WO2005082869A1 (en) * 2004-02-20 2005-09-09 Pharmacia & Upjohn Company Llc Method for the preparation of aryl ethers
AU2005217217B2 (en) * 2004-02-20 2008-03-06 Pharmacia & Upjohn Company Llc Method for the preparation of aryl ethers
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) * 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
GEP20084550B (en) * 2004-04-30 2008-11-25 Warner Lambert Co Substituted morpholine compounds for the treatment of central nervous system disorders
TW200718692A (en) 2005-04-22 2007-05-16 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
WO2006116151A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
EP1904843A2 (en) 2005-07-08 2008-04-02 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007231011A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
US20080020387A1 (en) * 2006-03-31 2008-01-24 Lawrence Donald G Biomarker-optimized adhd treatment
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2357340T3 (es) 2006-10-18 2011-04-25 Pfizer Products Inc. Compuestos de biaril éter urea.
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
CN101613347B (zh) * 2008-06-23 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 胺类化合物及其医药用途
ES2434250T3 (es) 2008-07-24 2013-12-16 Theravance, Inc. Compuestos de 3-(fenoxifenilmetil)pirrolidina
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
ES2397247T3 (es) 2008-11-14 2013-03-05 Theravance, Inc. Forma cristalina de un compuesto 4-[2-(2-fluorofenoximetil)fenil]piperidina
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP2012524098A (ja) * 2009-04-15 2012-10-11 セラヴァンス， インコーポレーテッド ３−（フェノキシピロリジン−３−イル−メチル）ヘテロアリール、３−（フェニルピロリジン−３−イルメトキシ）ヘテロアリールおよび３−（ヘテロアリールピロリジン−３−イルメトキシ）ヘテロアリール化合物
NZ597433A (en) * 2009-07-13 2013-12-20 Theravance Inc 3-phenoxymethylpyrrolidine compounds
WO2011011231A1 (en) * 2009-07-21 2011-01-27 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
US8778949B2 (en) * 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
EP2550252B1 (en) * 2010-03-22 2015-05-06 Theravance Biopharma R&D IP, LLC 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
CN103153950B (zh) 2010-10-11 2015-11-25 施万生物制药研发Ip有限责任公司 血清素再摄取抑制剂
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138405A (en) * 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
BE759013R (fr) * 1969-11-17 1971-05-17 Ici Ltd Derives de la
GB1382526A (en) * 1972-08-11 1975-02-05 Ici Ltd Morpholine derivatives
GB1412546A (en) * 1973-08-08 1975-11-05 Ici Ltd Morpholine derivatives
GB1427097A (en) * 1973-10-18 1976-03-03 Ici Ltd Optically-active morpholine derivatives
GB1469410A (en) * 1973-12-17 1977-04-06 Christiaens Sa A Benzodioxole derivatives
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1576216A (en) * 1975-01-29 1980-10-01 Yamanouchi Pharma Co Ltd 2-(7-indenyloxymethyl)-morpholine derivatives and process of producing them
CA1064927A (en) * 1975-01-29 1979-10-23 Yuji Kawashima Process of producing 2-(indenyloxymethyl) morpholine derivatives
CA1085841A (en) * 1976-05-19 1980-09-16 Jean-Marie Ferland Aryloxy proplamines, their preparation and use thereof

Also Published As

Publication number Publication date
AU4332779A (en) 1979-07-26
FR2430412A1 (fr) 1980-02-01
IE790107L (en) 1979-07-20
SI7910096A8 (sl) 1996-10-31
JPS6331455B2 (Direct) 1988-06-23
JPS54148739A (en) 1979-11-21
CS413391A3 (en) 1992-05-13
IE47727B1 (en) 1984-05-30
BG61056B2 (bg) 1996-09-30
IL56369A (en) 1984-05-31
DE19875005I2 (de) 2002-10-24
IL56369A0 (en) 1979-03-12
SE446727B (sv) 1986-10-06
KE3243A (en) 1982-12-03
YU9679A (en) 1983-12-31
GB2014981A (en) 1979-09-05
ATA40679A (de) 1982-12-15
DK156565C (da) 1990-02-05
FR2430412B1 (fr) 1987-06-26
SE7900498L (sv) 1979-07-21
FI71135C (fi) 1986-11-24
FR2442839A1 (fr) 1980-06-27
YU42094B (en) 1988-04-30
NZ189418A (en) 1981-03-16
GB2014981B (en) 1982-08-11
AU525954B2 (en) 1982-12-09
DE2901032A1 (de) 1979-08-02
FI71135B (fi) 1986-08-14
AT371813B (de) 1983-08-10
CA1128942A (en) 1982-08-03
NO146953B (no) 1982-09-27
NO146953C (no) 1983-01-05
FI790177A7 (fi) 1979-07-21
CH650245A5 (de) 1985-07-15
NO790205L (no) 1979-07-23
HK5783A (en) 1983-02-08
US4229449A (en) 1980-10-21
DE2901032C2 (de) 1996-05-30
MY8400018A (en) 1984-12-31
CY1172A (en) 1983-06-10
US4271160A (en) 1981-06-02
DK22679A (da) 1979-07-21
DK156565B (da) 1989-09-11

Similar Documents

Publication Publication Date Title
FR2442839B1 (Direct)
SE8503680D0 (sv) Indolderivat
MX9203187A (es) Compuestos que inhiben lipoxigenasa que contienen indol, benzafurano y benzotiofeno.
ES520195A0 (es) Procedimiento para preparar nuevos derivados de 3-ceto- 4,9,19-nor-esteroides.
FR2440946B2 (Direct)
IE43951L (en) 1-benzazolylalkyl-4-substituted-piperdines
DE3275184D1 (de) 2-(trisubstituted phenylimino)-imidazolines
FI812804A7 (fi) Antidepressiivisinä lääkeaineina käyttökelpoisia 2-(1,4-bentsodioksan-2-yylialkyyli)-imidatsoleja.
BG31473A3 (en) Fungicide means and method for fungus fighting
FI803727A7 (fi) 2,3-indolidioni-johdannaiset.
ES2018208B3 (es) Derivados de hidroxipirazol, procedimiento para su obtencion y su aplicacion contra microorganismos.
FI822616A7 (fi) Leimattu, immunologisesti aktiivinen aine.
DE3382578D1 (de) Ester aus 3-(3-substituierten amino-2-hydroxypropoxy)-4-substituierten 2,5-thiadiazolabkoemmlingen.
ES510302A0 (es) Procedimiento para la preparacion de 4-(3-trifluormetilfenil)-1,2,3,6-tetrahidropiridinas.
ES482949A1 (es) Un procedimiento para la preparacion de compuestos derivadosde piridoxina
IT8122397A0 (it) Derivati di 3-aril- e 3-eterociclil-2,3-diidro-1,4-benzossazina.
ES525249A0 (es) Procedimiento para la obtencion de 1,3 tiazolidinas sustituidas.
ES512696A0 (es) "procedimiento de obtener compuestos metilquinoxalin-1,4-dioxidicos".
FI810089A7 (fi) Uusia heterosyklisiä yhdisteitä, joita käytetään allergiavastaisina aineina.
ES517386A0 (es) Procedimiento para la preparacion de derivados de 2-(4h-1,2,4-triazol-4-il)-3-arokitiofeno.
ES263584Y (es) "azulejo-baldosa perfeccionado, de doble fondo".
JPS51133424A (en) A germicide and antiseptic for paper pulp industry
IT7820955V0 (it) Macchina perfezionata per la riproduzione di disegni.
IT8024108A0 (it) Derivati del2-solfinil-5-solfonil-1,3,4-tiadiazolo, procedimento per la fabbricazione di questi composti nonche' mezzi fungicidi che licontengono.
SU1432991A1 (ru) 4-Метил-5-(4-метилфениламино)-1,2,3-триазол, обладающий противовоспалительной активностью

Legal Events

Date Code Title Description
TP Transmission of property
TP Transmission of property
CD Change of name or company name